Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy
- PMID: 28916640
- DOI: 10.1161/CIRCULATIONAHA.117.029267
Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy
Abstract
Background: Atrial fibrillation (AF), the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM), is capable of producing symptoms that impact quality of life and is associated with risk for embolic stroke. However, the influence of AF on clinical course and outcome in HCM remains incompletely resolved.
Methods: Records of 1558 consecutive patients followed at the Tufts Medical Center Hypertrophic Cardiomyopathy Institute for 4.8±3.4 years (from 2004 to 2014) were accessed.
Results: Of the 1558 patients with HCM, 304 (20%) had episodes of AF, of which 226 (74%) were confined to symptomatic paroxysmal AF (average, 5±5; range, 1 to >20), whereas 78 (26%) developed permanent AF, preceded by 7±6 paroxysmal AF episodes. At last evaluation, 277 patients (91%) are alive at 62±13 years of age, including 89% in New York Heart Association class I or II. No difference was found in outcome measures for patients with AF and age- and sex-matched patients with HCM without AF. Four percent of patients with AF died of HCM-related causes (n=11), with annual mortality 0.7%; mortality directly attributable to AF (thromboembolism without prophylactic anticoagulation) was 0.1% per year (n=2 patients). Patients were treated with antiarrhythmic drugs (most commonly amiodarone [n=103] or sotalol [n=78]) and AF catheter ablation (n=49) or the Maze procedure at surgical myectomy (n=72). Freedom from AF recurrence at 1 year was 44% for ablation patients and 75% with the Maze procedure (P<0.001). Embolic events were less common with anticoagulation prophylaxis (4/233, 2%) than without (9/66, 14%) (P<0.001).
Conclusions: Transient symptomatic episodes of AF, often responsible for impaired quality of life, are unpredictable in frequency and timing, but amenable to effective contemporary treatments, and infrequently progress to permanent AF. AF is not a major contributor to heart failure morbidity or a cause of arrhythmic sudden death; when treated, it is associated with low disease-related mortality, no different than for patients without AF. AF is an uncommon primary cause of death in HCM virtually limited to embolic stroke, supporting a low threshold for initiating anticoagulation therapy.
Keywords: AF ablation; atrial fibrillation; hypertrophic cardiomyopathy; maze procedure.
© 2017 American Heart Association, Inc.
Comment in
-
Atrial Fibrillation in Hypertrophic Cardiomyopathy: New Light on an Old Problem.Circulation. 2017 Dec 19;136(25):2437-2439. doi: 10.1161/CIRCULATIONAHA.117.031743. Circulation. 2017. PMID: 29255123 No abstract available.
-
Letter by Zhang and Xu Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy".Circulation. 2018 Jun 5;137(23):2539. doi: 10.1161/CIRCULATIONAHA.118.034034. Circulation. 2018. PMID: 29866779 No abstract available.
-
Letter by Wang and Zhao Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy".Circulation. 2018 Jun 5;137(23):2540. doi: 10.1161/CIRCULATIONAHA.118.034035. Circulation. 2018. PMID: 29866780 No abstract available.
-
Response by Rowin et al to Letter Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy".Circulation. 2018 Jun 5;137(23):2541-2542. doi: 10.1161/CIRCULATIONAHA.118.034857. Circulation. 2018. PMID: 29866781 No abstract available.
Similar articles
-
Long-term clinical course after catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy.Heart Vessels. 2019 Mar;34(3):527-537. doi: 10.1007/s00380-018-1269-3. Epub 2018 Sep 25. Heart Vessels. 2019. PMID: 30255478
-
Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy.Circulation. 2023 Nov 28;148(22):1797-1811. doi: 10.1161/CIRCULATIONAHA.123.065037. Epub 2023 Nov 27. Circulation. 2023. PMID: 38011245 Review.
-
Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: atrial fibrillation type determines the success rate.Kardiol Pol. 2013;71(1):17-24. Kardiol Pol. 2013. PMID: 23348529 Clinical Trial.
-
Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy.Heart Rhythm. 2015 Jul;12(7):1438-47. doi: 10.1016/j.hrthm.2015.03.042. Epub 2015 Mar 23. Heart Rhythm. 2015. PMID: 25814420
-
Treatment of atrial fibrillation in hypertrophic cardiomyopathy.Anadolu Kardiyol Derg. 2006 Dec;6 Suppl 2:44-8. Anadolu Kardiyol Derg. 2006. PMID: 17162270 Review.
Cited by
-
Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy: Caveat Ablator.JACC Adv. 2024 Mar 15;3(5):100900. doi: 10.1016/j.jacadv.2024.100900. eCollection 2024 May. JACC Adv. 2024. PMID: 38939643 Free PMC article.
-
Importance of Paroxysmal Atrial Fibrillation and Sex Differences in the Prevention of Embolic Stroke in Hypertrophic Cardiomyopathy.Circ Rep. 2021 Apr 6;3(5):273-278. doi: 10.1253/circrep.CR-20-0101. Circ Rep. 2021. PMID: 34007941 Free PMC article.
-
Relation of atrial electromechanical delay to P-wave dispersion on surface ECG using vector velocity imaging in patients with hypertrophic cardiomyopathy.Ann Noninvasive Electrocardiol. 2021 Jan;26(1):e12801. doi: 10.1111/anec.12801. Epub 2020 Sep 24. Ann Noninvasive Electrocardiol. 2021. PMID: 32969115 Free PMC article.
-
Long-term clinical course after catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy.Heart Vessels. 2019 Mar;34(3):527-537. doi: 10.1007/s00380-018-1269-3. Epub 2018 Sep 25. Heart Vessels. 2019. PMID: 30255478
-
Complex organized atrial arrhythmia with alternation between two circuits involving probable epicardial connections: An ultra-high-density mapping study.HeartRhythm Case Rep. 2019 Apr 3;5(7):359-362. doi: 10.1016/j.hrcr.2019.03.010. eCollection 2019 Jul. HeartRhythm Case Rep. 2019. PMID: 31341776 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical